進智公共交通(00077.HK)中期扭虧為盈至269.6萬港元
格隆匯 11 月 27日丨進智公共交通(00077.HK)公佈,截至2020年9月30日止中期,公司實現收入1.44億港元,同比減少25.70%;期內淨利269.6萬港元,去年則虧損942.2萬港元,扭虧為盈;基本每股淨利0.99港仙。
自2020年1月下旬起,香港爆發的2019冠狀病毒病疫情嚴重衝擊了地公共交通行業。香港政府推行諸如學校停課、公共和私營部門員工在家辦公以及減少社交聚會等抗疫措施導致客流大幅下降。根據運輸署公佈的運輸數字,於截至2020年9月30日止6個月期間,綠色小巴士行業乘客量下跌28%。其他公共交通服務營辦商(包括港鐵及專營巴士等)乘客總數亦下跌約32%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.